<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525187</url>
  </required_header>
  <id_info>
    <org_study_id>Onychomycosis</org_study_id>
    <nct_id>NCT00525187</nct_id>
  </id_info>
  <brief_title>Onychomycosis: Diagnosis and Prevalence in Diabetic Neuropathic Patients</brief_title>
  <official_title>Onychomycosis: Diagnosis and Prevalence in Diabetic Neuropathic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vésale Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen-Cilag Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vésale Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of onychomycosis among diabetic patients is still a debated question as well&#xD;
      as the best way to diagnose the disease. We conducted a prospective study to assess the&#xD;
      prevalence of onychomycosis in diabetic neuropathic (DN) patients clinically suspected of&#xD;
      this disease and to assess the reliability of the diagnosis of onychomycosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From December 2000 to January 2005, we followed 100 successive diabetic patients, type 1 and&#xD;
      type 2, suffering from (DN). At baseline we assessed age, gender, medical history and&#xD;
      medications, foot insensitivity defined by a vibration perception threshold (VPT) &gt;25 volts&#xD;
      and onychomycosis by clinical diagnosis.&#xD;
&#xD;
      Multiple samples of the most affected nail, often the big toe, were taken. A potassium&#xD;
      hydroxide (KOH) test was done by 2 independent and blinded investigators and a culture in a&#xD;
      laboratory (lab) specialized in mycology.&#xD;
&#xD;
      Pictures of the nails and particularly of the sampled nail were taken. Apart from the&#xD;
      laboratory results, two independent and blinded dermatologists gave their diagnosis looking&#xD;
      at the pictures.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">January 2005</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <enrollment type="Actual">100</enrollment>
  <condition>Prevalence of Onychomycosis</condition>
  <condition>Diabetic Neuropathic Patients</condition>
  <condition>Diagnostic of Onychomycosis</condition>
  <condition>Patients Clinically Suspected of Onychomycosis</condition>
  <condition>Reliability of the Diagnosis of Onychomycosis</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion criteria were: presence of diabetes mellitus, type 1 or type 2, age between&#xD;
             18 and 80 years, neuropathy demonstrated by a VPT (Vibration Perception Threshold) &gt;25&#xD;
             volts tested with a neurothesiometer (Horwell Scientific, London, UK) and a clinical&#xD;
             diagnosis of onychomycosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion criteria were a history of psoriasis, systemic antifungal therapy during the&#xD;
             year preceding the enrolment, immunosuppression either by disease or treatment&#xD;
             induced.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle J DUMONT, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>CHU A Vésale</name>
      <address>
        <city>Montigny-le-Tilleul</city>
        <state>Hainaut</state>
        <zip>1190</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <study_first_submitted>August 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <last_update_submitted>September 4, 2007</last_update_submitted>
  <last_update_submitted_qc>September 4, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2007</last_update_posted>
  <keyword>onychomycosis</keyword>
  <keyword>diabetic neuropathic patients</keyword>
  <keyword>reliability of the diagnostic of onychomycosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

